Evotec places €116.1 million convertible bonds due 2033

Evotec placed €116.1 million of 7-year senior unsecured convertible bonds with a 2.625% coupon, a 110% redemption at maturity, and an initial conversion price of €6.5313, implying a 37.5% premium to the €4.75 reference share price. Net proceeds will fund Project Horizon, a transformation program, while a concurrent share placement was completed for hedging purposes and will not generate proceeds for Evotec. The company also reported Q1 2026 revenue down 21.7% year over year to €156.6 million, highlighting ongoing operating pressure despite adequate liquidity.

Analysis

This is less a financing event than a balance-sheet bridge to buy time for a turnaround that still has not proven self-funding. A seven-year convertible with a sub-4% yield and a sizable conversion premium effectively monetizes volatility while diluting equity only if the equity story repairs itself; that’s attractive for management, but it also signals lenders are underwriting optionality rather than fundamental cash generation. The concurrent hedge sale means the market will absorb real share supply near-term, so any post-issue strength should be treated as mechanical rather than conviction-driven.

The second-order issue is timing: the proceeds are earmarked for restructuring, but the business appears to need operating improvement before the next refinancing window, not after. If the transformation program fails to show margin expansion within the next 2-4 quarters, the bond likely trades more like a stressed credit than an equity-linked instrument, while the stock remains capped by dilution overhang and repeated capital-markets dependency. The current capital structure leaves limited room for a prolonged revenue recovery miss.

The contrarian angle is that the convert may actually reduce near-term insolvency risk enough to squeeze shorts, especially if investors had been positioned for a funding gap. That creates a tradable window where the equity can rally on de-risking even if the long-term equity case is unchanged. The key is whether management uses the reprieve to deliver sequential gross margin and cash burn improvement; absent that, the issue becomes a time-buying exercise rather than a re-rating catalyst.

Key Decisions for Investors

• Short EVO common into strength over the next 1-3 weeks: use the concurrent hedge-driven supply as an entry window; target downside as the market digests dilution and the financing resets expectations. Risk is a short squeeze if convert demand is interpreted as de-risking the balance sheet.
• Pair trade: long EVO convertible bonds / short EVO equity for 3-6 months, capturing volatility carry and dilution asymmetry. This works if the stock remains range-bound below the conversion strike; cut the short leg if management shows two consecutive quarters of meaningful cash burn improvement.
• If liquid access exists, buy downside protection via EVO puts or put spreads for 2-4 quarters out. The thesis is not bankruptcy, but a gap risk reprice if Project Horizon underdelivers and the market starts pricing a second financing before maturity.
• Do not chase MS on the headline; this is an execution fee, not a balance-sheet event. Any read-through to underwriting appetite is second-order and not enough to justify directional exposure.
• Set a catalyst watchlist for the next 2 earnings prints: if gross margin fails to expand and revenue remains volatile, treat rallies as sellable; if operating cash burn improves meaningfully, cover shorts and consider rotating into the convert.